Business Context and Reporting Period
This Form 8-K Current Report was filed by Protagonist Therapeutics, Inc. on May 31, 2018, covering events occurring on May 29, 2018. The company is an emerging growth company incorporated in Delaware. The filing primarily addresses the adoption of a new equity incentive plan and the results of the 2018 Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and equity plan administration rather than financial performance metrics.
Material Changes and Corporate Actions
Adoption of 2018 Inducement Plan
On May 29, 2018, the Board of Directors adopted the 2018 Inducement Plan to reserve 750,000 shares of common stock. This plan is designed exclusively for grants to individuals who were not previously employees or directors, serving as a material inducement for employment under NASDAQ Rule 5635(c)(4). The plan was approved without stockholder vote and mirrors the terms of the 2016 Equity Incentive Plan.
2018 Annual Meeting Results
Stockholders voted on two proposals at the Annual Meeting held on May 29, 2018:
- Proposal 1 (Election of Directors): All three Class II nominees were elected to serve until the 2021 Annual Meeting.
- Chaitan Khosla, Ph.D.: 16,094,476 For; 1,372,037 Withheld.
- William D. Waddill: 16,512,793 For; 953,720 Withheld.
- Lewis T. "Rusty" Williams, M.D., Ph.D.: 17,450,550 For; 15,963 Withheld.
- Proposal 2 (Ratification of Auditors): The selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018, was approved.
- Votes: 18,749,440 For; 337,597 Against; 150 Abstain.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, specific risks, or contingencies. The document is limited to reporting the adoption of the inducement plan and the voting outcomes of the annual meeting.
Investor Verification Checklist
- Verify the specific terms of the 2018 Inducement Plan in Exhibits 10.1, 10.2, and 10.3 to understand vesting schedules and grant conditions.
- Confirm the total number of shares authorized for issuance under the new plan (750,000) and its impact on potential dilution.
- Review the definitive proxy statement filed on April 18, 2018, for detailed background on the director nominees and auditor selection.
- Note that the company is classified as an emerging growth company and has elected not to use the extended transition period for new accounting standards.